openPR Logo
Press release

Oran Diagnostics Announces Appointments to Scientific Advisory Board

12-14-2010 10:03 AM CET | Health & Medicine

Press release from: LearnWell

BERWYN, PA, October 12, 2010—Oran Diagnostics, LLC, a specialized medical device company developing novel clinical diagnostic tools for applications across a broad spectrum of disease states, today announced that it has finalized the composition of its scientific advisory board with the addition of two new members. Comprised of world-renowned cardiologists and scientists, the advisory board will play an important role in guiding and participating in Oran’s research and clinical development programs.

“Oran is very fortunate to have such distinguished physicians and scientists as advisors to guide Oran in the development of the TCL Analyzer ™ and its lead product candidate, TCL-HF ™,” said Bruce J. Goldstein, President and Chief Executive Officer of Oran . “Each member of our Scientific Advisory Board is highly influential in their respective fields, and their collective experience will be of tremendous value in every facet of Oran’s development and clinical programs."

The two latest appointments to the Scientific Advisory Board are:

William T. Abraham, MD, FACP, FACC, FAHA, FESC, Director, Division of Cardiovascular Medicine, Professor of internal medicine, physiology and cell biology at The Ohio State University Medical Center. Deputy Director, Dorothy M. Davis Heart and Lung Research Institute; Chair of Excellence in Cardiovascular Medicine at Ohio State’s College of Medicine.

Dr. Abraham earned his medical degree from Harvard Medical School in Boston, Massachusetts, following which he completed his residency in Internal Medicine and fellowships in Cardiology and Heart Failure/Cardiac Transplantation at the University of Colorado Health Sciences Center. He previously held faculty appointments at the University of Colorado, the University of Cincinnati, and the University of Kentucky. He is board certified in Internal Medicine and in Cardiovascular Diseases. Dr. Abraham’s research interests include the role of the kidney in heart failure, neurohormonal mechanisms in heart failure, systemic and cardiac adrenergic activity in heart failure, and clinical drug and device trials in heart failure and cardiac transplantation. He has participated as Principal Investigator in more than 100 multicenter clinical drug and device trials. In addition to authoring more than 250 original papers, abstracts, book chapters, and review articles, Abraham serves on the editorial boards of several major journals including the Journal of Cardiac Failure, Congestive Heart Failure, and Journal Watch Cardiology. He is also a scientific reviewer for such publications as Circulation, the European Heart Journal, and the Journal of the American College of Cardiology.

Harry Ischiropoulos, Ph.D., Research Professor of Pediatrics and Pharmacology, Mahoney Institute of Neurological Science, Univ. of Pennsylvania.

Dr. Ischiropoulos received his PhD in Experimental Pathology from New York Medical College. After post-doctoral training at the University of Alabama in Birmingham he joined the Department of Biochemistry and Biophysics at the University of Pennsylvania as a Research Assistant Professor. In 1998 he moved to the Children’s Hospital of Philadelphia Research Institute where he is presently a Joseph Stokes Jr. Investigator and the Gisela and Dennis Alter Research Professor of Pediatrics and Pharmacology. He held a Parker B. Francis Fellowship in Pulmonary Research from 1993-1996 and was an Established Investigator of the American Heart Association from 1996 to 2001. Dr. Ischiropoulos serves on the Editorial Boards of Journal of Biological Chemistry and Free Radical Biology and Medicine where he is an Associate Editor. Laboratory investigations have been focused on the biological chemistry of nitric oxide and oxidative stress in the cardiovascular and central nervous systems. Dr. Ischiropoulos also served as a co-chair of the 2004 Gordon conference on Oxygen Radicals and is presently the president of the Society for Free Radical Biology and Medicine (2010-2012).

Drs. Abraham and Ischiropoulos join the following members of Oran’s Scientific Advisory Board:

* Frank Smart, MD, Chairman, Department of Cardiovascular Medicine, Atlantic Health (Morristown, NJ); Chief of Cardiology at the Gagnon Heart Hospital, Morristown Memorial Hospital.
* Offer Amir, MD, Director, Heart Failure, Department of Cardiovascular Medicine, Lady Davis Carmel Medical Center, Haifa, Israel.
* Aaron Ciechanover, MD, D.Sc., Distinguished University Professor, Faculty of Medicine, Technion-Israel Institute of Technology; Laureate, the 2004 Nobel Prize in Chemistry.
* Michael M. Givertz, MD, Medical Director, Heart Transplant and Circulatory Assist Program, Brigham and Women's Hospital, Boston, MA; Associate Professor, Harvard Medical School.
* Hyman Schipper, MD, PhD, FRCPC, Professor of Neurology & Medicine, at McGill University; Director, Centre for Neurotranslational Research, Lady Davis Institute, Jewish General Hospital (JGH), Montreal, Quebec.

About Oran Diagnostics

Oran Diagnostics, LLC is using its proprietary device (the TCL Analyzer ™) and method (thermochemiluminescence) to develop accurate, minimally invasive clinical tools for use in clinical diagnostics, and for drug discovery and development. The company’s proprietary technology is currently being applied in cardiovascular and neurodegenerative disease. Oran Diagnostics is headquartered in Berwyn, PA, with research and development facilities in Haifa, Israel. For more information, please visit www.orandx.com.

TCL-HF™ is a rapid, minimally invasive procedure for designed to aid in the risk stratification of patients diagnosed with heart failure. The TCL Analyzer™ measures lipid peroxidation in a small sample (50 microlitres) of blood serum. Using a highly sensitive, proprietary method of biomarker identification (thermochemiluminescence), TCL-HF™ measures the level of oxidative stress and oxidizability, which measurement correlates with the degree of disease severity. Analysis can be performed in a hospital or clinical laboratory in just minutes. TCL-HF™ provides a relevant, previously unavailable clinical data point that helps guide treatment options for patients with heart failure. The TCL Analyzer™ and TCL-HF™ are not currently cleared for use in the U.S. by the Food and Drug Administration.

Contact: Meredith Hegg
491 Baltimore Pike Suite 209
Springfield, PA 19064
Phone: 610-626-0175

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Oran Diagnostics Announces Appointments to Scientific Advisory Board here

News-ID: 155266 • Views: 779

More Releases from LearnWell

Bill Ringle Interviews Business Sales Expert Mark Satterfield on My Quest for Be …
Bill Ringle, America’s Business Growth Strategist, talked with Mark Satterfield, CEO of Gentle Rain Marketing, for the interview show My Quest for the Best. Philadelphia, PA, May 06, 2012 - Business growth strategist Bill Ringle interviewed Mark Satterfield, CEO of Gentle Rain Marketing and author of Unique Sales Stories, for My Quest for the Best. In this interview series, Ringle speaks with successful industry experts and outstanding business leaders about their
Oran Diagnostics Adds Reproductive Health to License Agreement with Carmel Diagn …
BERWYN, PA, February 14, 2011. Oran Diagnostics, LLC, a privately held diagnostics company, today announced that it has expanded its exclusive worldwide license agreement with Carmel Diagnostics, Ltd. of Kiryat Tivon, Israel, to include reproductive health. This expansion into reproductive medicine enables Oran to continue development of TCL-EV™, a rapid, non-invasive procedure that can be used to identify embryos with the greatest reproductive potential in patients undergoing IVF. TCL-EV™ is
Greater Philadelphia Business Owners Gather to Find Out How to “Become Famous …
Philadelphia, PA - January 14, 2011 - On January 11, 2011, Bill Ringle, founder of Rainmaker Academy, partnered with the Baiada Center at Drexel University to lead a half-day session titled “Become Famous In Your Niche so Business Comes to You”. Ringle led a full room of entrepreneurs and business owners through tips, insights and practical lessons in business development and marketing. While navigating topics such as defining your
Todd Wallach and Paul Sohmer, MD join Oran Diagnostics’ Board of Managers
BERWYN, PA, October 1, 2010—Oran Diagnostics, LLC, a specialized medical device company developing novel clinical diagnostic tools for applications across a broad spectrum of disease states, today announced that Todd Wallach and Paul Sohmer, MD have joined the Company’s Board of Managers. Mr. Wallach is the Chairman and Chief Executive Officer of Molecular Detection, Inc. (MDI). MDI is developing and commercializing a portfolio of "sample-to-answer" Detect-Ready™ molecular diagnostic tests for the

All 5 Releases


More Releases for Medicine

Tropical Medicine
Tropics are the most diverse regions on the earth . A large number of population live in this region where the weather varies throughout the year ( from scorching summer to chilly winter).This changing seasons induce the outbreaks of some fetal diseases known as tropical diseases which is unique only to the tropical areas. Malaria, Tuberculosis & AIDS are the major ones .Lack of sanitation, personal hygiene, proper
Precision Medicine Market - Future of Medicine, Challenges, Opportunities and So …
An emerging disease treatment approach which is built based upon individual variability in genes, environment, and personal lifestyle is referred to as precision medicine. The precision medicine can also be termed as personalized medicine. Precision medicine is a mode of medicine that joins standardization with individualization. The benefit offered by this approach of treatment include accurate treatment prediction and strategies for prevention of a particular disease that works for a
Regenerative Medicine Landscape
Boston, MA ReportsWorldwide has announced the addition of a new report title Regenerative Medicine Landscape to its growing collection of premium market research reports. The competitive landscape for regenerative medicine continues to evolve. As private sector investment in active players continues, efforts by governments in the US and EU are helping to advance the field, including the recent passage of the 21st Century Cures Act in the US, providing a special status
Lighted Mirror Medicine Cabinets
Lighted Mirror Medicine cabinet is a small cabinet, usually with a mirror on the front, which is attached to the wall in a bathroom. Scope of the Report: This report focuses on the Lighted Mirror Medicine Cabinets in United States market, to split the market based on manufacturers, states, type and application. Sample Report Request: https://www.reportsandmarkets.com/sample-request/united-states-lighted-mirror-medicine-cabinets-to-2022-1622832 Market Segment by Applications can be divided into Household Commercial There are 17 Chapters to deeply display the United States Lighted
Nuclear Medicine/Radiopharmaceuticals Market
Radiopharmaceuticals are unique medicinal formulations that contain radioisotopes and are used in clinical applications for diagnosis and therapy. The facilities and procedures for production, use, and storage of radiopharmaceuticals are subject to license approval either by national or regional authorities such as Nuclear Regulatory Commission (NRC) of U.S, Atomic Energy Commission (AEC) of U.S., or Atomic Energy Regulatory Board (AERB) of India. Licensing includes compliance regarding pharmaceutical preparations and use
Precision Medicine Market
Precision medicine is an approach of treatment that has been derived on the basis of individual variability in environment, genes and lifestyle of each person. This novel approach assists medical practitioners and researchers to understand various treatment needs in order to prevent specific diseases. It allows for highly precise targeting of medication for treatment of various diseases, which is expected to lead to high adoption by medical practitioners and researchers.